SEC Filings
State Street Reports 4.8% Passive Stake In BioCryst, Measured At September's End
The holding covered 12,294,412 shares, while BioCryst raised its revenue outlook and pulled back from internal research.
BioCryst Pharmaceuticals (BCRX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The holding covered 12,294,412 shares, while BioCryst raised its revenue outlook and pulled back from internal research.
Earnings
Initial stocking at the new pharmacy boosted third-quarter sales; BioCryst cautions that quarterly figures may diverge from patient demand.
SEC Filings
The hereditary angioedema drugmaker held its ORLADEYO forecast and trimmed its adjusted operating expense outlook to $415 million to $425 million.